At the clinical level, however, the combination of RT with anti-PD-L1 immunotherapy for the radical treatment of locally advanced HNSCC failed to show a benefit in the JAVELIN trial [18]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.